Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001

被引:246
作者
Fridkin, SK
Hageman, J
McDougal, LK
Mohammed, J
Jarvis, WR
Perl, TM
Tenover, FC
机构
[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[2] Johns Hopkins Univ Hosp, Dept Hosp Epidemiol & Infect Control, Baltimore, MD 21287 USA
关键词
D O I
10.1086/346207
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infections caused by Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS; minimum inhibitory concentration [MIC], greater than or equal to4 mug/mL), including vancomycin-intermediate S. aureus (VISA; MIC, 8 mug/mL), are a new clinical and public health dilemma. Prospective surveillance and a nested case-control study of patients in the United States infected with SA-RVS was conduced from March 1999 through December 2000. Control patients were persons infected with oxacillin-resistant S. aureus (MIC of vancomycin, less than or equal to2 mug/mL). Among 19 case patients, 4 infections were due to VISA and 15 were due to non-VISA SA-RVS. Case patients with and those without VISA infection had similar clinical presentations and outcomes; the overall attributable mortality rate was 63%. Isolates recovered from case patients had heterogeneous pulsed-field gel electrophoresis banding patterns, regardless of the MIC of vancomycin. Neither dialysis nor chronic renal failure were predictive of case status compared with control status. Independent risk factors for being a case patient included antecedent vancomycin use and prior oxacillin-resistant S. aureus infection 2 or 3 months before the current infection.
引用
收藏
页码:429 / 439
页数:11
相关论文
共 27 条
[1]  
Anderson D, 2001, CLIN INFECT DIS, V33, P1090
[2]  
[Anonymous], 1999, MMWR-MORBID MORTAL W, V48, P707
[3]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[4]   Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates [J].
Boyle-Vavra, S ;
Berke, SK ;
Lee, JC ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :272-277
[5]  
Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V48, P1165
[6]   Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin [J].
Climo, MW ;
Patron, RL ;
Archer, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1747-1753
[7]   Survey of infections due to Staphylococcus species:: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Diekema, DJ ;
Pfaller, MA ;
Schmitz, FJ ;
Smayevsky, J ;
Bell, J ;
Jones, RN ;
Beach, M .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S114-S132
[8]  
Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542
[9]   Vancomycin-intermediate Staphylococcus aureus in a home health-care patient [J].
Hageman, JC ;
Pegues, DA ;
Jepson, C ;
Bell, RL ;
Guinan, M ;
Ward, KW ;
Cohen, MD ;
Hindler, JA ;
Tenover, FC ;
McAllister, SK ;
Kellum, ME ;
Fridkin, SK .
EMERGING INFECTIOUS DISEASES, 2001, 7 (06) :1023-1025
[10]   Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: A systematic review [J].
Harris, AD ;
Karchmer, TB ;
Carmeli, Y ;
Samore, MH .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (07) :1055-1061